Moderna [MRNA] vs Vertex [VRTX] Detailed Stock Comparison

Moderna Inc.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Moderna Inc. wins in 4 metrics, Vertex Pharmaceuticals Inc. wins in 15 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Moderna Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) 24.97 28.40 Moderna Inc.
Price-to-Book Ratio 2.47 5.92 Moderna Inc.
Debt-to-Equity Ratio 15.09 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio -0.91 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -5.92 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) -145.16% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) -126.40% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -28.87% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -14.51% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-2.08B $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 77.67% 1.24% Moderna Inc.
Price-to-Sales Ratio (TTM) 11.06 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $16.92B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 8.71 8.83 Moderna Inc.
Gross Profit Margin (TTM) 33.14% 85.39% Vertex Pharmaceuticals Inc.
Revenue per Share (TTM) $5 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-7.26 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 1.34 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 18.71% 1.78% Vertex Pharmaceuticals Inc.

Moderna Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

MRNA
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Moderna Inc.7.49%3.05%3.72%-1.55%94.84%58.98%
Vertex Pharmaceuticals Inc.0.76%-2.03%-0.35%-9.68%-7.51%-5.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Moderna Inc.77.67%-63.84%-77.10%153.71%153.71%153.71%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Moderna Inc. vs Vertex Pharmaceuticals Inc.

MetricMRNAVRTX
Market Information
Market Cap i$20.96B$109.45B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i6,250,5021,057,061
90 Day Avg. Volume i6,358,6141,272,097
Last Close$49.06$428.34
52 Week Range$22.28 - $59.55$362.50 - $507.92
% from 52W High-17.62%-15.67%
All-Time High$497.49 (Aug 09, 2021)$519.88 (Nov 04, 2024)
% from All-Time High-90.14%-17.61%
Growth Metrics
Quarterly Revenue Growth-0.30%0.10%
Quarterly Earnings Growth-0.29%0.31%
Financial Health
Profit Margin (TTM) i-1.45%0.33%
Operating Margin (TTM) i-1.26%0.40%
Return on Equity (TTM) i-0.29%0.23%
Debt to Equity (MRQ) i15.0910.91
Cash & Liquidity
Book Value per Share (MRQ)$21.95$73.49
Cash per Share (MRQ)$14.68$26.01
Operating Cash Flow (TTM) i$-1,872,999,936$3.63B
Levered Free Cash Flow (TTM) i$-1,326,499,968$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Moderna Inc. vs Vertex Pharmaceuticals Inc.

MetricMRNA (Apr 24, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i24.9728.40
Forward P/E i-11.7519.95
PEG Ratio i-0.910.88
Price to Sales (TTM) i11.069.22
Price to Book (MRQ) i2.475.92
Market Capitalization
Market Capitalization i$20.96B$109.45B
Enterprise Value i$16.92B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i8.718.83
Enterprise to EBITDA i-5.9221.78
Risk & Other Metrics
Beta i1.340.37
Book Value per Share (MRQ) i$21.95$73.49

Financial Statements Comparison: Moderna Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMRNA (2025)VRTX (2025)
Revenue/Sales i1.92B12.00B
Cost of Goods Sold i868.00M1.65B
COGS % of Revenue i45.2%13.8%
Gross Profit i1.05B10.35B
Gross Margin i54.8%86.2%
Research & Development i3.13B4.04B
Operating Income (EBIT) i-3.07B4.55B
Operating Margin i-159.9%37.9%
EBITDA i-2.54B5.25B
EBITDA Margin i-132.0%43.7%
Pre-Tax Income i-2.77B4.64B
Pre-Tax Income % of Revenue i-144.0%38.7%
Income Tax i54.00M690.00M
Income Tax % of Revenue i2.8%5.7%
Net Income (Profit) i-2.82B3.95B
Profit Margin i-146.8%32.9%

Balance Sheet & Liquidity Metrics

MetricMRNA (2025)VRTX (2025)
Cash & Equivalents i2.60B5.08B
Total Current Assets i6.54B11.20B
Total Current Assets % of Revenue i340.5%93.3%
Total Current Liabilities i1.99B3.86B
Total Current Liabilities % of Revenue i103.4%32.2%
Long-Term Debt i1.26B1.95B
Long-Term Debt % of Revenue i65.7%16.3%
Total Shareholders Equity i8.65B18.67B
Retained Earnings i7.22B13.56B
Retained Earnings % of Revenue i375.8%113.0%
Property, Plant & Equipment i1.39B1.56B

Cash Flow Statement Comparison

MetricMRNA (2025)VRTX (2025)
Operating Cash Flow i-1.97B3.77B
Operating Cash Flow % of Revenue i-102.2%31.4%
Capital Expenditures i-192.00M-437.60M
Free Cash Flow i-2.08B3.19B
FCF Margin i-108.0%26.6%
Debt Repayment i-22.00M-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricMRNAVRTX
Shares Short i60.65M4.02M
Short Ratio i7.112.80
Short % of Float i18.71%1.78%
Shares Outstanding i394.00M253.99M
Float Shares i368.43M253.24M
% Held by Insiders i7.32%0.21%
% Held by Institutions i77.05%97.60%
% Held by Public i15.63%2.19%

Dividend Analysis & Yield Comparison: Moderna Inc. vs Vertex Pharmaceuticals Inc.

MetricMRNAVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A